TMCnet News
Sarah Cannon Research Institute Names Dawn Sauro to Executive TeamSarah Cannon Research Institute (SCRI), the research arm of HCA's global cancer enterprise, Sarah Cannon, today announced it has named Dawn Sauro as the new president of the company's full service contract research organization (CRO), Development Innovations. In her role, Sauro will provide executive oversight for Sarah Cannon's line of business that specializes in clinical research management for first-in-human through proof-of-concept trials. "Dawn brings more than 20 years of experience in clinical development and operations from the pharmaceutical and healthcare industry," said Dee Anna Smith, SCRI chief executive officer. "Her executive leadership will help us continue to enhance our service offering and further our mission of advancing therapies for patients." Most recently, Sauro served as senior vice president and general manager of hematology and oncology at inVentive Health Clinical in Raleigh, .C. Previously, she served as vice president of operations for PRA International in Raleigh and director of clinical operations for PPD Inc. at the company's Seattle office. Sauro holds a bachelor's of science degree from the University of Rhode Island. "Throughout her career, Dawn has gained deep industry expertise in the design and development of clinical trials," said Smith. "With her leadership, we look forward to expanding our capabilities and achieving new milestones with our pharmaceutical and biotech company partners to improve patient outcomes through clinical research." Sauro will join the SCRI leadership team in Chicago for the American Society of Clinical Oncology (ASCO®) annual meeting and formally begin her position at the company's Nashville headquarters in June. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is the research arm of HCA's global cancer enterprise, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world's leading clinical research organizations conducting community-based clinical trials in oncology, cardiology and orthopedics through affiliations with a network of more than 1,000 physicians across the United States and United Kingdom. SCRI has led more than 170 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in nearly 80 percent of approved cancer therapies in the last 10 years. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), SCRI Development Innovations. For more information, visit sarahcannon.com. About SCRI Development Innovations SCRI Development Innovations (SCRI Innovations) is a global, full-service, oncology-focused contract research organization (CRO) specializing in clinical development services. As the CRO of Sarah Cannon's research arm, Sarah Cannon Research Institute (SCRI), SCRI Innovations leverages SCRI's expert physician leadership to design and implement optimal clinical trials that effectively and efficiently lead to rapid clinical decisions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005124/en/ |
